Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454779 · ClinicalTrials.gov registry record · Phase 2
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
A Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT00454779: Completed Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, sponsored by Amgen.
NCT00454779 is a Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck that has completed, run by Amgen. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00454779, a Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent SCCHN.
Primary Outcome
The time from the date of randomization to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later) during the first-line treatment phase.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Panitumumab
Study Locations (20)
California
- Research Site - Duarte
- Research Site - La Jolla
- Research Site - La Verne
- Research Site - Los Angeles
- Research Site - Santa Cruz
District of Columbia
- Research Site - Washington D.C.
- Research Site - Washington D.C.
- Research Site - Washington D.C.
- Research Site - Washington D.C.
Florida
- Research Site - Lakeland
- Research Site - Miami
- Research Site - New Port Richey
- Research Site - Orlando
Colorado
- Research Site - Aurora
- Research Site - Denver
Arizona
- Research Site - Tucson
Arkansas
- Research Site - Jonesboro
Connecticut
- Research Site - Norwich
Delaware
- Research Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2007-01-01 |
| Est. Completion | 2014-01-01 |
| Phase | Phase 2 |
What the finished NCT00454779 record still lists
NCT00454779 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT00454779 names 20 study sites across 9 states, led by California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT00454779 about?
NCT00454779 is a clinical study titled "PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response". This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over se...
What is the current status of trial NCT00454779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2007-01-01. Estimated completion is 2014-01-01.
What conditions does trial NCT00454779 study?
This clinical trial studies the following conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT00454779?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT00454779?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00454779 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00454779's enrollment target sits among peer trials
113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI